Articles tagged with Cancer Patients
The NCCN Annual Conference will debut a new hybrid format featuring in-person events at a new venue, allowing for hallway conversations and networking opportunities. The conference will also showcase more than 100 abstract poster presentations on various oncology-related categories.
A study by researchers at TUM found that gut bacteria play a crucial role in liver regeneration. The microbiome produces short-chain fatty acids, which are essential for liver cell growth and division. In mice treated with antibiotics, liver regeneration was delayed or not possible, but a
The CALYPSO study assesses the efficacy of combined MET and PD-L1 inhibition in patients with MET-driven metastatic papillary renal cancer. Response rates were 29% for all patients and 53% for those with MET-driven tumors, with improved progression-free survival observed in MET-driven status.
Researchers identified microglia as key players in chemo brain inflammation, suggesting a potential target for treatment. In a mouse study, deleting microglia restored memory and lowered brain inflammation after paclitaxel treatment.
Researchers have identified markers associated with an increased risk of metastasis in patients with metastatic pheochromocytoma, allowing for personalized clinical management. The study also identifies patients who could benefit from immunotherapy treatments, paving the way for potential new therapies.
A Rutgers study found no statistically significant improvements in patient or caregiver anxiety, depression, or psychological distress in palliative care interventions. The researchers identified conceptual and methodological problems in the literature, including excluding patients with existing mental health conditions from studies.
A new treatment regimen combining high-dose abatacept and ruxolitinib has shown to significantly improve survival rates among cancer patients with cardiotoxicity from immune checkpoint inhibitors. The experimental treatment reduced myotoxicity-related mortality by 90% compared to standard-of-care corticosteroids.
The ESMO Targeted Anticancer Therapies Congress 2023 features presentations on drug discovery and development for various targets, precision medicine, and early clinical trial methodology. Keynote lectures highlight novel insights in mutational signatures and epigenetic therapies.
A decade-long international study has linked genetic changes in kidney cancer to patient outcomes, identifying four groups of patients based on specific genes. The findings suggest that tumour DNA sequencing may provide a more effective way to predict patient risk of kidney cancer recurrence.
A study published in Nature Communications reveals that platinum accumulates in healthy cells surrounding cancer cells, particularly fibroblasts, and induces gene activation associated with poor response to chemotherapy. Periostin levels serve as a marker of TGF-β activity in fibroblasts and predict treatment benefit.
A new study links genetic changes in kidney cancer to patient outcomes, identifying four groups of patients based on mutation presence. This research may lead to more effective prediction of recurrence risk and personalized treatment for thousands of patients annually.
A study of 37,000 pediatric head and neck cancer patients found significant decreases in care receipt and survival time with increasing social determinants of health vulnerability. The findings highlight the need for targeted interventions to address social vulnerabilities in pediatric cancer care.
Researchers have discovered that cancer patients who don't respond to immunotherapy often lack CD5+ dendritic cells, which are essential for effective T cell activity. Boosting these cells may help more patients benefit from immunotherapy.
Experts warn that scrapping England's long term plan for cancer will lead to wide variations in access to effective treatments and quality of care. The current proposal jettisons decades of global consensus on the need for dedicated cancer plans.
A new algorithm uses patient-reported outcomes to identify patients with cancer who are at increased odds of having unplanned emergency department visits. The algorithm, which calculates a symptom complexity score, has shown that patients with high complexity scores are three times more likely to use the ED.
A new machine learning model combines fusion gene profiling, serum PSA level, and Gleason score to predict prostate cancer recurrence with improved accuracy. The model outperformed clinical data alone and provided valuable insights into the mechanism of disease progression.
Researchers have developed a novel prognostic index to predict survival outcomes in gastric cancer patients. The inflammation-combined prognostic index (ICPI) combines three biomarkers - lymphocyte-to-monocyte ratio, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio - to provide a personalized prognosis for each patient.
Men with non-metastatic castration-resistant prostate cancer treated with enzalutamide experienced sharp reductions in PSA levels, leading to improved survival rates. A 50% decrease in PSA was associated with lower risk of metastases and longer survival time.
A recent study confirms that pancreatic cancer rates are rising faster in women than men, particularly among younger women and Black women. The rate of pancreatic cancer among women under the age of 55 increased by 2.4% compared to men of the same age, highlighting a significant disparity in mortality rates between the sexes.
The February issue of the CHEST journal features 37 articles exploring various topics in chest medicine, including asthma, COPD, and pulmonary vascular disease. The journal also highlights its equity topic collection, focusing on conditions that affect women, such as pulmonary arterial hypertension and sarcoidosis.
The ESMO Gynaecological Cancers Congress 2023 will present the latest treatments and insights for ovarian, uterine, cervical, and rare gynaecological cancers. Around 80 studies will be presented on strategies to overcome PARP inhibitors mechanisms of resistance in ovarian cancer.
Researchers at Harvard's Wyss Institute developed a method to fine-tune CAR-T cell stimulation using artificial antigen-presenting scaffolds. This approach enhances consistency and potency of resulting CAR-T cell products, allowing for better cancer treatment outcomes.
Researchers investigated a remote dietary intervention to reduce chronic cancer-related fatigue in lymphoma survivors, with encouraging preliminary data suggesting effectiveness. Participants showed significant improvement in self-reported fatigue and overall healthful eating patterns.
Researchers at Uppsala University developed a prognostic method using a combination of immune cells to provide clearer disease prognoses and predict which patients will respond best to immunotherapy. The method was shown to be associated with patient fate in several types of cancer.
Researchers investigated the effects of everolimus on the STAT3/HIF-1α/VEGF pathway in TP53 mutant cell lines and xenograft models. Everolimus treatment significantly inhibited cell growth and reduced tumor angiogenesis and lymphangiogenesis.
A phase 3 clinical trial of nearly 700 patients with early-stage lung cancer found that sublobar resection surgery, removing part of the affected lobe, was as effective as traditional lobectomy in terms of disease-free and overall survival. Patients who underwent sublobar resection also showed modestly better lung function.
The grant aims to eliminate barriers and facilitate access to early phase cancer clinical trials for medically underserved communities. Researchers will develop and implement a multilevel program to improve referrals and enrollment, exploring the impact of remote clinical trials on enhancing diversity in trials.
A study by University of Gothenburg researchers found a significant association between methotrexate use and an increased risk of basal cell carcinoma, squamous cell carcinoma, and cutaneous malignant melanoma. The study suggests that higher doses of methotrexate may increase the risk of SCC and BCC, while no dose-response relationship...
A study published in eLife found that one in two cancer patients developed long COVID-19 symptoms persisting beyond six months after initial infection. Female cancer patients were more likely to experience long COVID-19 compared to men, and most cases could be managed as outpatients.
Engineers at the University of Waterloo developed AI technology to predict breast cancer treatment effectiveness, allowing doctors to prescribe personalized treatments and reduce unnecessary side effects. The new algorithm uses synthetic correlated diffusion imaging images to forecast patient responses to chemotherapy.
Researchers at Karolinska Institutet have developed a new type of CAR T-cell therapy that effectively attacks and destroys ovarian cancer cells, significantly prolonging the lives of mice with the disease. The treatment has shown promising results in reducing tumor size and curing several mice.
Researchers evaluate an integrated NGS system, delivering accurate diagnoses in under 24 hours and expanding targeted treatments available to patients with myeloid neoplasms. The assay identified 80-92% of genetic variants, demonstrating promising results for accelerating precision therapies.
People living with dementia are more likely to have cancer diagnosed at an advanced stage and receive less treatment, negatively affecting survival. Review authors provide pragmatic recommendations for clinicians treating cancer in patients with dementia.
Researchers at Cedars-Sinai Cancer have developed a non-invasive test that can detect and profile prostate cancers in microscopic amounts. The test, known as the EV Digital Scoring Assay, has the potential to spare patients from unnecessary treatment-related side effects and direct them to effective therapies.
Researchers developed a new device to identify key membrane proteins in urine indicative of brain tumors. This could lead to early detection and increased survival rates for patients.
A systematic review and meta-analysis found that MRI-based surveillance after surgical treatment can detect clinically occult local recurrences, potentially improving patient outcomes. The study included 19 studies and showed a significant association between high-intensity surveillance and the detection of local recurrences.
A $1.1 million Department of Defense grant supports Augusta University research linking prostate cancer and cardiovascular diseases. Dr. Avirup Guha's research aims to investigate the aging process, exploring the role of nicotinamide adenine dinucleotide in this connection.
Researchers report an updated analysis from a phase I study of mivavotinib, a spleen tyrosine kinase inhibitor, in patients with relapsed/refractory B-cell lymphoma. The study showed a 45% overall response rate and median duration of response of 28.1 months in the overall cohort.
Patients living in Southern states with expanded Medicaid were more likely to receive early treatment for invasive breast cancer. Despite this, the proportion of patients undergoing treatments actually decreased across all states.
Researchers at Rice University have developed light-activated nanoscale drills that can kill pathogenic fungi, providing a potential new treatment option for fungal infections. The molecular machines target the mitochondria of fungal cells, disrupting cellular metabolism and leading to cell death.
Researchers developed a method to measure individual biological response to therapy using functional near-infrared spectroscopy, enabling real-time evaluation of radiotherapy's impact on patients. This technique allows for tailored radiation doses to optimize treatment and improve outcomes.
Researchers analyzed over 500,000 patient records and found that patients diagnosed at age 70 were nearly twice as likely to be passed over for post-surgical radiation therapy. This significant gap in treatment recommendations suggests that cognitive heuristics play a major role in physician decision-making.
The SWOG S1416 clinical trial demonstrated the efficacy of PARP inhibitor veliparib in patients with triple-negative breast cancer and a 'BRCA-like' phenotype. Patients treated with veliparib experienced longer progression-free survival times compared to those receiving chemotherapy alone, with median PFS of 5.9 months versus 4.2 months.
Researchers at Saint Louis University found that COVID-19 vaccination does not interfere with cancer immunotherapy in previously vaccinated patients. The study supports recommending vaccination to patients with cancer, including those receiving systemic therapies.
A Yale-led clinical trial found improved rates of survival and reduced risk of recurrence in patients taking osimertinib for non-small cell lung cancer. The study showed prolonged disease-free survival and reduced local- and distant-recurrence of symptoms.
A novel form of chemoimmunotherapy has been proven to be a promising treatment for canine cancer, extending the lives of terminally ill dogs. The therapy uses modified Mesenchymal Stem Cells carrying a potent 'kill-switch' that induces anti-cancer immunity and improves quality of life.
A study found that immune checkpoint inhibitors enhance chemotherapy-induced neuropathic pain by blocking interaction between macrophages and neurons via PD1-PDL1 synergy. This discovery could lead to the development of therapeutic alternatives to prevent pain while maintaining anti-neoplastic effects.
The world's first international clinical guidelines have been created to prevent and treat heart complications in children undergoing cancer treatment. The guidelines cover cardiovascular disease assessment, screening, and follow-up for pediatric patients receiving various cancer treatments.
Researchers identified a subset of mutations within tumor mutation burden that remain persistent and visible to the immune system, increasing likelihood of response to immunotherapy. This finding enables clinicians to more accurately select patients for clinical trials or predict clinical outcomes with immune checkpoint blockade.
A phase 2 clinical trial combining immunotherapy and targeted therapy showed a 24.3% confirmed response rate and 5-month median progression-free survival among patients with BRAF V600 mutations. The treatment also demonstrated increased durability, with 57% of patients remaining on treatment for more than 6 months.
Researchers developed a translational step forward in treating brain tumors using intraventricular immunovirotherapy, which has shown safety and efficacy in recent clinical trials. This approach uses oncolytic herpes simplex virus type-1 to target high-grade glioma with promising results.
Researchers found that female patients with diffuse large B-cell lymphoma treated in the afternoon had reduced mortality rates and cancer recurrence compared to those treated in the morning. The study suggests that timing chemotherapy delivery according to an individual's circadian clock may improve treatment outcomes.
A phase 3 trial found that adding nab-paclitaxel to a standard gemcitabine plus cisplatin regimen did not significantly extend median overall survival for patients with advanced biliary tract cancers, but provided benefits for subsets of patients. The treatment also showed improved response rates and progression-free survival times.
A new study led by Mayo Clinic researchers found that women carrying specific genetic changes, such as BRCA1 and BRCA2, have a twofold increased risk of developing contralateral breast cancer. Premenopausal women with these mutations are more likely to develop cancer in both breasts.
Researchers found that certain gene signaling pathways, such as interferon γ and beta-catenin, can lead to tumor hyperprogression after immunotherapy. Targeting these pathways may prevent hyperprogression in preclinical models.
New research reveals elevated suicide rates among adults undergoing cancer surgery, with significant increases observed in certain cancers and demographics
A Cancer Research UK-funded clinical trial found that chemotherapy before surgery reduces the chance of colon cancer returning within 2 years by 28%. The study involved 1,053 patients and showed significant benefits in terms of preventing cancer recurrence.
Researchers developed the Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) questionnaire to identify key symptoms and side effects associated with radionuclide therapy. The tool aims to improve patient-centered care and guide treatment decisions for prostate cancer patients.
Researchers found poor adherence to surgical quality metrics in lung cancer patients, with only 40% receiving minimally invasive surgery and one-third receiving adequate lymph node sampling. Adherence to guidelines was associated with improved overall survival rates.
A new personalized treatment for bile duct cancer has shown remarkable results, with patients surviving for up to two years when treated with the drug futibatinib. The Phase II clinical trial found that the drug was more effective at reducing tumor size and producing modest side effects compared to chemotherapy.